High-Dose Ceftriaxone in Elderly Patients with Enterococcal Infective Endocarditis: Population Pharmacokinetics of Free Ceftriaxone and Dose Optimization.

IF 4.3 2区 医学 Q1 INFECTIOUS DISEASES
Beatriz Fernández Rubio, Fernando Docobo Pérez, Laura Herrera Hidalgo, Luis Eduardo López-Cortés, Rafael Luque Márquez, José Manuel Lomas Cabezas, Luis Fernando López-Cortés, Marta Mejías Trueba, Ana Belén Guisado Gil, Alicia Gutiérrez Valencia, Arístides de Alarcón González, María Victoria Gil Navarro
{"title":"High-Dose Ceftriaxone in Elderly Patients with Enterococcal Infective Endocarditis: Population Pharmacokinetics of Free Ceftriaxone and Dose Optimization.","authors":"Beatriz Fernández Rubio, Fernando Docobo Pérez, Laura Herrera Hidalgo, Luis Eduardo López-Cortés, Rafael Luque Márquez, José Manuel Lomas Cabezas, Luis Fernando López-Cortés, Marta Mejías Trueba, Ana Belén Guisado Gil, Alicia Gutiérrez Valencia, Arístides de Alarcón González, María Victoria Gil Navarro","doi":"10.3390/antibiotics14050508","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Ampicillin plus ceftriaxone (AC) is a first-line treatment for <i>Enterococcus faecalis</i> infective endocarditis (IE). Its administration in outpatient parenteral antibiotic treatment (OPAT) programs is challenging. The design of a ceftriaxone regimen suitable for OPAT requires deep knowledge of ceftriaxone pharmacokinetics (PK). <b>Objective:</b> We aim to explore ceftriaxone PK in elderly patients and propose dose regimens adapted to OPAT to maintain synergistic concentrations (Cs) with ampicillin against <i>E. faecalis</i>. <b>Methods:</b> We conducted a prospective observational pharmacokinetic study on patients (>55 years old) affected by <i>E. faecalis</i> IE. Ceftriaxone free concentration was measured at three time-points: before the administration (C<sub>min</sub>) and two and four hours after ceftriaxone administration (C<sub>2</sub> and C<sub>4</sub>). Both structural and covariate population pharmacokinetic models were built. Monte Carlo simulations of six ceftriaxone dosages were performed and the probability of target attainment (PTA) of an optimal Cs range was analyzed. The pharmacokinetic/pharmacodynamic index (PK/PD) to predict efficacy was defined as maintaining free ceftriaxone concentrations superior to the Cs at 50-100% of the dosing interval (fT ≥ Cs ≥ 50-100% of the dosing interval). Ceftriaxone dosing regimens were considered optimal if at least 90% of the simulated population was able to achieve the defined PK/PD targets. <b>Results:</b> Twenty-four episodes from 16 patients were included. Mean free ceftriaxone concentration pre-dose, +2 h, and +4 h were C<sub>min</sub> = 7.8 ± 6.5 mg/L, C<sub>2</sub> = 34 ± 26.5 mg/L, and C<sub>4</sub> = 22.7 ± 19.7 mg/L, respectively. A two-compartment model with first-order absorption and elimination best described the data. Ceftriaxone one-hour infusions only achieved the minimum PK/PD target when the 2 g/12 h regimen was tested. On the other hand, ceftriaxone continuous infusion maintained a Cs above the PK/PD target for 100% of the dosing interval using ceftriaxone 4-6 g regimens. <b>Conclusions:</b> Our findings suggest that the optimal ceftriaxone exposure may be achieved using high-dose continuous infusions to ensure an ampicillin-killing effect when treating <i>E. faecalis</i> IE.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"14 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12108460/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics14050508","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ampicillin plus ceftriaxone (AC) is a first-line treatment for Enterococcus faecalis infective endocarditis (IE). Its administration in outpatient parenteral antibiotic treatment (OPAT) programs is challenging. The design of a ceftriaxone regimen suitable for OPAT requires deep knowledge of ceftriaxone pharmacokinetics (PK). Objective: We aim to explore ceftriaxone PK in elderly patients and propose dose regimens adapted to OPAT to maintain synergistic concentrations (Cs) with ampicillin against E. faecalis. Methods: We conducted a prospective observational pharmacokinetic study on patients (>55 years old) affected by E. faecalis IE. Ceftriaxone free concentration was measured at three time-points: before the administration (Cmin) and two and four hours after ceftriaxone administration (C2 and C4). Both structural and covariate population pharmacokinetic models were built. Monte Carlo simulations of six ceftriaxone dosages were performed and the probability of target attainment (PTA) of an optimal Cs range was analyzed. The pharmacokinetic/pharmacodynamic index (PK/PD) to predict efficacy was defined as maintaining free ceftriaxone concentrations superior to the Cs at 50-100% of the dosing interval (fT ≥ Cs ≥ 50-100% of the dosing interval). Ceftriaxone dosing regimens were considered optimal if at least 90% of the simulated population was able to achieve the defined PK/PD targets. Results: Twenty-four episodes from 16 patients were included. Mean free ceftriaxone concentration pre-dose, +2 h, and +4 h were Cmin = 7.8 ± 6.5 mg/L, C2 = 34 ± 26.5 mg/L, and C4 = 22.7 ± 19.7 mg/L, respectively. A two-compartment model with first-order absorption and elimination best described the data. Ceftriaxone one-hour infusions only achieved the minimum PK/PD target when the 2 g/12 h regimen was tested. On the other hand, ceftriaxone continuous infusion maintained a Cs above the PK/PD target for 100% of the dosing interval using ceftriaxone 4-6 g regimens. Conclusions: Our findings suggest that the optimal ceftriaxone exposure may be achieved using high-dose continuous infusions to ensure an ampicillin-killing effect when treating E. faecalis IE.

大剂量头孢曲松治疗老年肠球菌感染性心内膜炎:游离头孢曲松的人群药代动力学及剂量优化。
背景:氨苄西林加头孢曲松(AC)是治疗粪肠球菌感染性心内膜炎(IE)的一线药物。它的管理在门诊肠外抗生素治疗(OPAT)计划是具有挑战性的。设计适合OPAT的头孢曲松方案需要对头孢曲松药代动力学(PK)有深入的了解。目的:探讨头孢曲松在老年患者中的PK,并提出适合OPAT的剂量方案,以维持与氨苄西林对粪肠球菌的协同浓度(Cs)。方法:我们对受粪肠杆菌感染的患者(55岁)进行了一项前瞻性观察药代动力学研究。在给药前(Cmin)和给药后2小时和4小时(C2和C4)三个时间点测量头孢曲松游离浓度。建立了结构和协变量群体药代动力学模型。对头孢曲松的6种剂量进行了蒙特卡罗模拟,并分析了最佳Cs范围的目标实现概率(PTA)。预测疗效的药代动力学/药效学指数(PK/PD)定义为在50-100%给药间隔内保持头孢曲松游离浓度优于Cs (fT≥Cs≥50-100%给药间隔)。如果至少90%的模拟人群能够达到定义的PK/PD目标,则认为头孢曲松给药方案是最佳的。结果:纳入16例患者的24次发作。Cmin = 7.8±6.5 mg/L, C2 = 34±26.5 mg/L, C4 = 22.7±19.7 mg/L,给药前、+ 2h、+ 4h头孢曲松平均游离浓度分别为Cmin = 7.8±6.5 mg/L, C2 = 34±26.5 mg/L。具有一阶吸收和消除的两室模型最好地描述了数据。头孢曲松1小时输注2 g/12 h方案仅达到最低PK/PD目标。另一方面,使用头孢曲松4-6 g方案,头孢曲松连续输注在100%的给药间隔内保持高于PK/PD目标的Cs。结论:我们的研究结果表明,在治疗粪肠杆菌IE时,高剂量连续输注头孢曲松可以达到最佳暴露量,以确保氨苄西林的杀伤效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antibiotics-Basel
Antibiotics-Basel Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
7.30
自引率
14.60%
发文量
1547
审稿时长
11 weeks
期刊介绍: Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信